Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK 1,473.00
+14.50 (0.99%)
Aug 15, 2025, 9:00 AM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Reimbursement | 138.35M | Log In | Log In | Log In | Log In | Upgrade |
Reimbursement Growth | -28.16% | Log In | Log In | Log In | Log In | Upgrade |
Milestone | 138.90M | Log In | Log In | Log In | Log In | Upgrade |
Milestone Growth | - | Log In | Log In | Log In | Log In | Upgrade |
License | 277.81K | Log In | Log In | Log In | Log In | Upgrade |
Other | 242.11M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 93.98% | Log In | Log In | Log In | Log In | Upgrade |
DARZALEX Royalties | 1.93B | Log In | Log In | Log In | Log In | Upgrade |
DARZALEX Royalties Growth | 21.89% | Log In | Log In | Log In | Log In | Upgrade |
Kesimpta Royalties | 308.65M | Log In | Log In | Log In | Log In | Upgrade |
Kesimpta Royalties Growth | 37.07% | Log In | Log In | Log In | Log In | Upgrade |
TEPEZZA Royalties | 102.37M | Log In | Log In | Log In | Log In | Upgrade |
TEPEZZA Royalties Growth | -0.45% | Log In | Log In | Log In | Log In | Upgrade |
Other Product Royalties | 65.42M | Log In | Log In | Log In | Log In | Upgrade |
Other Product Royalties Growth | 51.14% | Log In | Log In | Log In | Log In | Upgrade |
Collaboration | 60.15M | Log In | Log In | Log In | Log In | Upgrade |
Collaboration Growth | 28.33% | Log In | Log In | Log In | Log In | Upgrade |
Net Product Sales | 242.11M | Log In | Log In | Log In | Log In | Upgrade |
Net Product Sales Growth | 93.29% | Log In | Log In | Log In | Log In | Upgrade |
J&J | 2.00B | Log In | Log In | Log In | Log In | Upgrade |
J&J Growth | 20.29% | Log In | Log In | Log In | Log In | Upgrade |
Novartis | 391.99M | Log In | Log In | Log In | Log In | Upgrade |
Novartis Growth | 66.25% | Log In | Log In | Log In | Log In | Upgrade |
BioNTech | 120.71M | Log In | Log In | Log In | Log In | Upgrade |
BioNTech Growth | -32.63% | Log In | Log In | Log In | Log In | Upgrade |
Pfizer | 74.04M | Log In | Log In | Log In | Log In | Upgrade |
Pfizer Growth | 22.64% | Log In | Log In | Log In | Log In | Upgrade |
Other Collaboration Partner | 277.81K | Log In | Log In | Log In | Log In | Upgrade |
Other Collaboration Partner Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Roche | 102.93M | Log In | Log In | Log In | Log In | Upgrade |
Roche Growth | 1.10% | Log In | Log In | Log In | Log In | Upgrade |
AbbVie | 54.73M | Log In | Log In | Log In | Log In | Upgrade |
AbbVie Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Denmark | 2.75B | Log In | Log In | Log In | Log In | Upgrade |
Denmark Growth | - | Log In | Log In | Log In | Log In | Upgrade |
United States | 125.29M | Log In | Log In | Log In | Log In | Upgrade |
Japan | 116.82M | Log In | Log In | Log In | Log In | Upgrade |